NCT05836571 2026-04-21
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT02867592 2026-04-13
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04200443 2026-01-05
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06156410 2025-11-14
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT04551430 2025-11-12
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05182164 2025-10-07
PEMBROCABOSARC
Institut Bergonié
Phase 2 Recruiting
NCT05135975 2025-08-12
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nationwide Children's Hospital
Phase 2 Recruiting
NCT01755195 2024-01-03
Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed